S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
NASDAQ:TBPH

Theravance Biopharma - TBPH Stock Forecast, Price & News

$10.79
+0.09 (+0.84%)
(As of 12/8/2022 02:10 PM ET)
Add
Compare
Today's Range
$10.50
$10.85
50-Day Range
$9.65
$11.34
52-Week Range
$7.53
$13.17
Volume
5,478 shs
Average Volume
889,948 shs
Market Capitalization
$726.92 million
P/E Ratio
0.96
Dividend Yield
N/A
Price Target
$14.67

Theravance Biopharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
36.7% Upside
$14.67 Price Target
Short Interest
Bearish
13.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Theravance Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$22,361 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.96) to ($0.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

759th out of 1,027 stocks

Pharmaceutical Preparations Industry

368th out of 503 stocks

TBPH stock logo

About Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Stock News Headlines

SVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)
Company News for Sep 20, 2022
Theravance Biopharma Rises 6% On News Of Share Buyback
Theravance To Buy Back $250 Mln Of Shares
See More Headlines
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Company Calendar

Last Earnings
11/02/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
Fax
N/A
Employees
359
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+35.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-199,430,000.00
Net Margins
1,646.84%
Pretax Margin
-118.56%

Debt

Sales & Book Value

Annual Sales
$55.31 million
Book Value
($4.59) per share

Miscellaneous

Free Float
64,132,000
Market Cap
$726.92 million
Optionable
Optionable
Beta
0.54

Key Executives

  • Rick E. Winningham
    Chairman & Chief Executive Officer
  • Andrew Asa Hindman
    Chief Financial Officer & Senior Vice President
  • Vijay Sabesan
    Senior Vice President-Technical Operations
  • Philip D. Worboys
    Senior VP-Research & Translational Science
  • Bradford J. Shafer
    Secretary, Executive VP & General Counsel













TBPH Stock - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
View TBPH analyst ratings
or view top-rated stocks.

What is Theravance Biopharma's stock price forecast for 2023?

3 equities research analysts have issued 12-month price targets for Theravance Biopharma's shares. Their TBPH share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's share price to reach $14.67 in the next year. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for TBPH
or view top-rated stocks among Wall Street analysts.

How have TBPH shares performed in 2022?

Theravance Biopharma's stock was trading at $11.05 at the beginning of the year. Since then, TBPH stock has decreased by 2.7% and is now trading at $10.75.
View the best growth stocks for 2022 here
.

When is Theravance Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TBPH earnings forecast
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. The biopharmaceutical company earned $13.19 million during the quarter, compared to the consensus estimate of $13.55 million. During the same period in the previous year, the company earned ($1.16) EPS.

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baupost Group LLC MA (19.92%), Weiss Asset Management LP (11.07%), Weiss Asset Management LP (11.07%), Vanguard Group Inc. (8.92%), BlackRock Inc. (7.58%) and Park West Asset Management LLC (2.85%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Vijay Sabesan.
View institutional ownership trends
.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $10.75.

How much money does Theravance Biopharma make?

Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $724.23 million and generates $55.31 million in revenue each year. The biopharmaceutical company earns $-199,430,000.00 in net income (profit) each year or $11.26 on an earnings per share basis.

How many employees does Theravance Biopharma have?

The company employs 359 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.

This page (NASDAQ:TBPH) was last updated on 12/8/2022 by MarketBeat.com Staff